ClinicalTrials.gov
ClinicalTrials.gov Menu

Azithromycin Treatment for the Airway Microbiome in Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03736629
Recruitment Status : Not yet recruiting
First Posted : November 9, 2018
Last Update Posted : December 4, 2018
Sponsor:
Collaborator:
Northwestern University
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
The purpose of this study to determine whether the bacteria inside the lungs of people with asthma can be modified (changed) if they are given an antibiotic and if this change is associated with an improvement in asthma symptoms.

Condition or disease Intervention/treatment Phase
Asthma Chronic Drug: Azithromycin Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The AZITRAMBA Trial: Azithromycin Treatment for the Airway Microbiome in Asthma
Estimated Study Start Date : January 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : February 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Placebo Comparator: Placebo
8 weeks of placebo capsule once daily by mouth
Drug: Placebo
Placebo

Active Comparator: Azithromycin
8 weeks of Azithromycin (250 mg) capsule once daily by mouth
Drug: Azithromycin
8 weeks of Azithromycin (250 mg) once daily by mouth
Other Name: Zithromax




Primary Outcome Measures :
  1. Asthma Control Test (ACT) score change from baseline over 8 weeks [ Time Frame: 8 weeks ]
    Score ranging from 0 to 40 indicating the degree of asthma symptoms. Lower score indicating worse asthma symptoms.


Secondary Outcome Measures :
  1. Forced expiratory volume (FEV1) change from baseline over 8 weeks [ Time Frame: 8 weeks ]
    Volume of air exhaled in 1 second on a forced expiration, indicating the degree of airflow obstruction in asthma

  2. Sputum eosinophils change from baseline over 8 weeks [ Time Frame: 8 weeks ]
    Proportion of 'eosinophils', an inflammatory cell seen in the airways of people with asthma, indicating the degree of inflammation

  3. Sputum neutrophils change from baseline over 8 weeks [ Time Frame: 8 weeks ]
    Proportion of 'neutrophils', an inflammatory cell seen in the airways of people with asthma, indicating the degree of inflammation

  4. COMPEX score of asthma severity from baseline over 8 weeks [ Time Frame: 8 weeks ]
    A weighted scoring system that describes asthma symptoms done on a daily basis

  5. Microbiome Shannon alpha-diversity score change from baseline to 8 weeks [ Time Frame: 8 weeks ]
    A measure of the diversity of the bacteria in the sputum or oral sample; that is, how many different types of bacteria are present. This value decreases in severe asthma

  6. Microbiome beta-diversity score change from baseline to 8 weeks [ Time Frame: 8 weeks ]
    A second measure of the diversity of the bacteria in the sputum or oral sample; that is, how many different types of bacteria are present. This value decreases in severe asthma

  7. Microbiome change in relative proportion of top 10 genera from baseline to 8 weeks [ Time Frame: 8 weeks ]
    A measure of how many of the top types of bacteria are present in the sputum or oral sample. Value changes with asthma



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria (All participants):

  1. Age 18 - 55 years
  2. Able to provide informed consent
  3. QTc < 440 ms on ECG
  4. Smoking history < 10 pack-years

Inclusion Criteria for subjects with poorly controlled asthma

  1. Methacholine PC20 < 16 mg/ml
  2. Albuterol response > 12% on FEV1 after 4 puffs of albuterol
  3. Ability to use combination ICS + LABA
  4. Meet definition for Th2-low asthma: peripheral blood eosinophil count < 300 and exhaled nitric oxide level < 30 ppb.

Exclusion Criteria (All participants)

  1. History of allergy or intolerance to any medications used in this study
  2. Medication exclusions:

    1. Current use of medications that prolong QTc interval
    2. Current use of omalizumab or other ant-IgE therapies
    3. Current use of anti IL 5 therapies
    4. Current use of anticoagulants
    5. Prednsione or other oral steroids within past 3 months
  3. Pregnancy or lactation
  4. Other respiratory or inflammatory disorders (e.g., sarcoidosis, emphysema)
  5. Pre-existing liver disease (AST or ALT >10% above the upper limit of normal)
  6. Smoking within the last 6 months
  7. Exacerbation of asthma in past 3 months
  8. Affected by a hearing disorder
  9. Clinically significant medical condition (e.g., heart failure, seizure disorder) which may in-crease risk as determined by study investigator
  10. Corrected QT interval > 450 msec. Patients with known cardiac history or prolonged QT interval on a screening EKG are excluded given the small but real potential for macrolide-related side effects.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03736629


Contacts
Contact: Steve White, MD 773-702-2004 swhite@medicine.bsd.uchicago.edu
Contact: Spring Maleckar 773-834-4053 smalecka@medicine.bsd.uchicago.edu

Locations
United States, Illinois
Northwestern University Not yet recruiting
Chicago, Illinois, United States, 60201
Contact: Lew Smith, MD         
University of Chicago Not yet recruiting
Chicago, Illinois, United States, 60637
Contact: Steve White, MD         
Sponsors and Collaborators
University of Chicago
Northwestern University
Investigators
Principal Investigator: Steve White, MD University of Chicago

Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT03736629     History of Changes
Other Study ID Numbers: IRB17-1287
First Posted: November 9, 2018    Key Record Dates
Last Update Posted: December 4, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: We will share individual participant data that is de-identified available to all qualified investigators
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database (e.g., sequencing information will be deposited in a genetics bio-bank).
Access Criteria: All qualified investigators who sign appropriate data use agreements and material transfer agreements with the University of Chicago and Northwestern University

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by University of Chicago:
Asthma
Azithromycin
Microbiome
Sputum

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases